The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: microencapsulated peptide vaccines. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
80+ innovations will shape the pharmaceutical industry
See Also:
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Microencapsulated peptide vaccines is a key innovation area in the pharmaceutical industry
Peptide vaccine microsphere formulations refer to a type of vaccine delivery system in which small particles made up of biodegradable polymers are used to encapsulate peptide antigens. These microspheres protect the peptide antigens from degradation and improve their stability and immunogenicity. When administered to a host, the microspheres slowly release the antigens over an extended period, allowing for a sustained immune response.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 780+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of microencapsulated peptide vaccines.
Key players in microencapsulated peptide vaccines – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to microencapsulated peptide vaccines
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| GSK | 1070 | Unlock Company Profile |
| C. H. Boehringer Sohn | 797 | Unlock Company Profile |
| Johnson & Johnson | 756 | Unlock Company Profile |
| AstraZeneca | 745 | Unlock Company Profile |
| Sanofi | 709 | Unlock Company Profile |
| Merck | 610 | Unlock Company Profile |
| Zoetis | 505 | Unlock Company Profile |
| Takeda Pharmaceutical | 460 | Unlock Company Profile |
| Pfizer | 430 | Unlock Company Profile |
| Valneva | 393 | Unlock Company Profile |
| Regeneron Pharmaceuticals | 324 | Unlock Company Profile |
| F. Hoffmann-La Roche | 270 | Unlock Company Profile |
| Gilead Sciences | 251 | Unlock Company Profile |
| Centre National de la Recherche Scientifique | 207 | Unlock Company Profile |
| Inovio Pharmaceuticals | 190 | Unlock Company Profile |
| Vir Biotechnology | 176 | Unlock Company Profile |
| Moderna | 160 | Unlock Company Profile |
| Mitsubishi Chemical Group | 159 | Unlock Company Profile |
| VLP Therapeutics | 156 | Unlock Company Profile |
| Molecular Templates | 154 | Unlock Company Profile |
| National Research Council of Canada | 146 | Unlock Company Profile |
| Curevac | 137 | Unlock Company Profile |
| Vertex Pharmaceuticals | 133 | Unlock Company Profile |
| Theraclone Sciences | 131 | Unlock Company Profile |
| X4 Pharmaceuticals | 130 | Unlock Company Profile |
| Verneuil Participations | 120 | Unlock Company Profile |
| Novartis | 101 | Unlock Company Profile |
| Bristol-Myers Squibb | 98 | Unlock Company Profile |
| Celltrion | 91 | Unlock Company Profile |
| Academia Sinica | 89 | Unlock Company Profile |
| Meiji | 87 | Unlock Company Profile |
| Erasmus MC | 84 | Unlock Company Profile |
| Temasek | 84 | Unlock Company Profile |
| US Department of Health and Human Services | 81 | Unlock Company Profile |
| Bharat Biotech | 79 | Unlock Company Profile |
| MacroGenics | 77 | Unlock Company Profile |
| Novavax | 76 | Unlock Company Profile |
| BioNTech | 73 | Unlock Company Profile |
| Bavarian Nordic | 69 | Unlock Company Profile |
| Codagenix | 68 | Unlock Company Profile |
| Oswaldo Cruz Foundation | 66 | Unlock Company Profile |
| Intervet | 66 | Unlock Company Profile |
| Geeks On Call | 64 | Unlock Company Profile |
| Compagnie Merieux Alliance | 63 | Unlock Company Profile |
| Les Laboratoires Servier | 62 | Unlock Company Profile |
| Pomona Ricerca | 62 | Unlock Company Profile |
| CareGroup | 61 | Unlock Company Profile |
| XBiotech | 60 | Unlock Company Profile |
| Nitto Denko | 59 | Unlock Company Profile |
| International AIDS Vaccine Initiative | 58 | Unlock Company Profile |
Source: GlobalData Patent Analytics
GSK is one of the leading patent filers in microencapsulated peptide vaccines. It is involved in the development of various peptide vaccines. GSK also acquired Affinivax, a leading company in vaccine development, primarily for cancer.
In terms of application diversity, Vertex Pharmaceuticals leads the pack, while Celltrion and Sanofi stood in second and third positions, respectively. By means of geographic reach, Molecular Templates held the top position, followed by XBiotech and Vertex Pharmaceuticals.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
